Cardiomyopathy: Difference between revisions
(/* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...) Tag: Manual revert |
(/* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...) |
||
| Line 44: | Line 44: | ||
|- | |- | ||
| bgcolor="LightGreen"|2. Timely and adequate preparation for transition of [[care]] from [[pediatric]] to [[adult]] services, including [[joint]] [[consultations]], is recommended in all [[adolescents]] with [[cardiomyopathy]]. ''([[ESC #Level of Evidence|Level of Evidence: C]])'' | | bgcolor="LightGreen"|2. Timely and adequate preparation for transition of [[care]] from [[pediatric]] to [[adult]] services, including [[joint]] [[consultations]], is recommended in all [[adolescents]] with [[cardiomyopathy]]. ''([[ESC #Level of Evidence|Level of Evidence: C]])'' | ||
|} | |||
<br> | |||
<u> Recommendations for [[Diagnostic]] [[Work-up]] in [[Cardiomyopathies]]. </u> | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|1. It is recommended that all [[patients]] with . ''([[ESC #Level of Evidence|Level of Evidence: C]])'' | |||
|- | |||
| bgcolor="LightGreen"|2. It is recommended that all [[patients]] with ''([[ESC #Level of Evidence|Level of Evidence: C]])'' | |||
|} | |||
<br> | |||
<u> Recommendations for [[Laboratory Tests]] in the [[Diagnosis]] of [[Cardiomyopathies]]. </u> | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|1. ''([[ESC #Level of Evidence|Level of Evidence: C]])'' | |||
|} | |||
<br> | |||
<u> Recommendations for [[Echocardiographic]] [[Evaluation]] in [[Patients]] with [[Cardiomyopathies]]. </u> | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|1. ''([[ESC #Level of Evidence|Level of Evidence: C]])'' | |||
|} | |||
<br> | |||
<u> Recommendations for [[Cardiac] [[Magnetic Resonance]] Indication in [[Patients]] with [[Cardiomyopathies]]. </u> | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|1. ''([[ESC #Level of Evidence|Level of Evidence: C]])'' | |||
|} | |||
<br> | |||
<u> Recommendations for [[Computed Tomography]] and [[Nuclear Imaging]] </u> | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|1. ''([[ESC #Level of Evidence|Level of Evidence: C]])'' | |||
|} | |||
<br> | |||
<u> Recommendations for [[Genetic Counselling]] and Testing in [[Cardiomyopathies]]. </u> | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]] | |||
|- | |||
|colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Genetic Counselling]] | |||
|- | |||
| bgcolor="LightGreen"|1. ''([[ESC #Level of Evidence|Level of Evidence: C]])'' | |||
|} | |} | ||
Revision as of 08:13, 9 November 2023
For patient information click here
| Cardiomyopathy | |
 | |
|---|---|
| Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium {Autopsy findings}. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology |
|
Cardiomyopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Guidelines |
|
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy |
|
Case Studies |
|
Cardiomyopathy On the Web |
|
American Roentgen Ray Society Images of Cardiomyopathy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lina Ya'qoub,MD; Mahshid Mir, M.D. [2], Cafer Zorkun, M.D., Ph.D. [3], Raviteja Guddeti, M.B.B.S. [4]; Edzel Lorraine Co, DMD, MD[5]
Synonyms and keywords: Myocardiopathy; cardiac muscle disease; heart muscle disease.
Overview
Historical Perspective
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
2023 ESC Guideline Recommendations [1]
Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
| Class I |
| 1. It is recommended that all patients with cardiomyopathy and their relatives have access to multidisciplinary teams with expertise in the diagnosis and management of cardiomyopathies. (Level of Evidence: C) |
| 2. Timely and adequate preparation for transition of care from pediatric to adult services, including joint consultations, is recommended in all adolescents with cardiomyopathy. (Level of Evidence: C) |
Recommendations for Diagnostic Work-up in Cardiomyopathies.
| Class I |
| 1. It is recommended that all patients with . (Level of Evidence: C) |
| 2. It is recommended that all patients with (Level of Evidence: C) |
Recommendations for Laboratory Tests in the Diagnosis of Cardiomyopathies.
| Class I |
| 1. (Level of Evidence: C) |
Recommendations for Echocardiographic Evaluation in Patients with Cardiomyopathies.
| Class I |
| 1. (Level of Evidence: C) |
Recommendations for [[Cardiac] Magnetic Resonance Indication in Patients with Cardiomyopathies.
| Class I |
| 1. (Level of Evidence: C) |
Recommendations for Computed Tomography and Nuclear Imaging
| Class I |
| 1. (Level of Evidence: C) |
Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
| Class I |
| ESC #Genetic Counselling |
| 1. (Level of Evidence: C) |
Case Studies
de:Kardiomyopathie nl:Cardiomyopathie no:Kardiomyopati simple:Cardiomyopathy sr:Кардиомиопатија sv:Hjärtmuskelsjukdom
- ↑ Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C; et al. (2023). "2023 ESC Guidelines for the management of cardiomyopathies". Eur Heart J. 44 (37): 3503–3626. doi:10.1093/eurheartj/ehad194. PMID 37622657 Check
|pmid=value (help).